Business Wire

Virgin Media O2 Selects Mavenir for its Open RAN Deployment

17.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Virgin Media O2 has selected Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, as its Open Radio Access Network (Open RAN) vendor. Mavenir will also be the prime integrator, providing its Open virtualised Radio Access Network (Open vRAN) solution for sites on Virgin Media O2’s network.

Virgin Media O2 will work with Mavenir to roll out a scalable Open vRAN solution as part of its network evolution plans and adopt a more flexible and cloud-native architecture.

Mavenir’s Open vRAN solution is built from the ground up to be cloud-native, with fully containerised microservices allowing it to be deployed easily on any cloud. Mavenir’s Open vRAN O-RAN compliant solution works on open interfaces supporting O-RAN Split 7.2x and Split 2.

It further disaggregates into Distributed Unit (DU) and Centralised Unit (CU). These entities work as containerised network functions running on Commercial Off the Shelf (COTS) hardware containing Intel processors.

Designed to support multiple Fronthaul splits simultaneously, the vRAN solution provides a vendor-agnostic and future-proof architecture, leveraging Virgin Media O2’s network infrastructure assets.

Mavenir’s Open RAN system will consist of fully virtualised L1, L2 vRAN SW and will operate on Intel Xeon Scalable Processors, along with Intel vRAN Accelerator ACC100 and Intel 800 series Ethernet adapters. The delivery will also feature Mavenir’s OpenBeam™ Radios including massive MIMO, 3rd party O-RAN based Radio Units (O-RU) for open Fronthaul, network monitoring and optimisation.

Jeanie York, Chief Technology Officer at Virgin Media O2, said: “Through digitalising our networks, we’re seamlessly integrating our infrastructure to get more value from our existing assets. Extending our collaboration with Mavenir to the RAN for the first time will help us establish a future-proof Open vRAN architecture, unlocking the benefits of a multi-vendor open interface while allowing us to rapidly benefit from an end-to-end network solution.”

Pardeep Kohli, President and CEO at Mavenir, said: “Mavenir’s Open vRAN cloud-native approach presents new pathways for automated networks to deliver on the use cases and data demands of today and beyond - driving network elasticity, flexibility and best-in-class automation. The Mavenir OpenBeam radio portfolio fully complements Virgin Media O2’s full spectrum requirements and we look forward to playing an active role in unlocking network automation and openness in the RAN.”

Cristina Rodriguez, Vice President Network and Edge Group at Intel, said: “Open and virtualised RAN represents the future: a flexible and scalable software-defined network. Intel is pleased to collaborate with and be part of the Virgin Media O2 technology journey with Mavenir. Together we are delivering innovation, performance, and we are working towards more sustainable networks.”

Notes to Editors

About Virgin Media O2

Virgin Media O2 launched on 1 June 2021, combining the UK’s largest and most reliable mobile network with a broadband network offering the fastest widely-available broadband speeds. It is a customer-first organisation that brings a range of connectivity services together in one place with a clear mission: to upgrade the nation. Virgin Media O2 is the corporate brand of the 50:50 joint venture between Liberty Global and Telefónica SA, and one of the UK’s largest businesses. The company has 47 million UK connections across broadband, mobile, TV and home phone. Its own fixed network currently passes 16.1 million premises alongside a mobile network that covers 99% of the nation’s population with 4G, and more than 1,600 towns and cities with 5G services targeting 50% population coverage in 2023.

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mavenir PR Contacts:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye